NEWS
EXPLORE OUR LATEST MILESTONES AND SUCCESS STORIES
Innovation • Excellence • Impact
Gaya Pharma News - Clinical Research & Healthcare Innovation
Stay informed about our latest innovations and initiatives in clinical research across Africa
Gaya Pharma and MAH2 Join Forces for Prostate Cancer Awareness Month
Every November, the world comes together to raise awareness about prostate cancer. In partnership with Morocco Africa for Healthy Horizon (MAH2), Gaya Pharma organized a dedicated awareness session targeting men over 45 to promote early detection and break taboos around men's health in Africa.
Gaya Pharma Expands to Côte d'Ivoire to Strengthen Clinical Research in West Africa
Gaya Pharma, Africa's leading full-service CRO, proudly announces the launch of its new subsidiary Gaya Pharma CI in Abidjan. This strategic milestone marks a decisive step in advancing clinical research, driving real-world evidence generation, and expanding patient access to innovative therapies across West Africa.
Gaya Pharma and MAH2 Join Forces for Prostate Cancer Awareness Month
Every November, the world comes together to raise awareness about prostate cancer, a disease that affects millions of men globally and is one of the most common cancers among men over the age of 45.
At Gaya Pharma, we believe that awareness, education, and early detection are key to saving lives. This year, in partnership with the non-profit association Morocco Africa for Healthy Horizon (MAH2), we organized a dedicated awareness session to engage men in our community and highlight the importance of prostate health.
Raising Awareness Among Men Over 45
The awareness session, held in November, specifically targeted men above the age of 45, who are at higher risk of developing prostate cancer. Many participants often lack access to accurate information, regular screening, and preventive healthcare services. Our goal was to bridge this gap by:
- Educating participants about risk factors, symptoms, and preventive measures
- Promoting early detection through regular medical check-ups and screening
- Encouraging open dialogue on men's health, which remains a sensitive but critical subject in many African communities
This initiative was not only informative but also interactive, giving participants the opportunity to ask questions and discuss concerns directly with healthcare professionals.
A Commitment to Better Health in Africa
As an African Contract Research Organization (CRO) deeply rooted in the continent, Gaya Pharma goes beyond clinical research to actively contribute to public health awareness and patient education. Partnering with MAH2, our sister non-profit organization, allows us to extend our impact beyond clinical trials by bringing concrete benefits to local communities.
Together, we share the same mission:
- Improving access to healthcare across Africa
- Supporting patient education and awareness campaigns
- Building healthier communities through prevention and early action
Why Prostate Cancer Awareness Matters
- Prostate cancer is among the leading cancers in men worldwide
- In Africa, limited awareness and late diagnosis often result in poor outcomes
- Raising awareness during Prostate Cancer Awareness Month (Movember) provides an opportunity to break taboos, encourage screening, and save lives
By addressing this health challenge, Gaya Pharma and MAH2 reaffirm their joint commitment to advancing healthcare access and improving patient outcomes across Africa.
Looking Ahead
This initiative is part of a broader commitment by Gaya Pharma to integrate clinical research excellence with community health engagement. We believe that research, awareness, and patient support must go hand in hand to create sustainable impact in Africa.
As we continue to expand our presence in Africa through Gaya Pharma CI in Abidjan and other initiatives, we remain dedicated to combining science with compassion, and innovation with accessibility.
Gaya Pharma Expands to Côte d'Ivoire to Strengthen Clinical Research and Patient Access to Innovative Therapies
Gaya Pharma, Africa's leading full-service Contract Research Organization (CRO), proudly announces the official launch of its new subsidiary Gaya Pharma CI, based in Abidjan. This strategic milestone marks a decisive step in our mission to advance clinical research, drive real-world evidence (RWE) generation, and expand patient access to innovative therapies across West Africa.
Côte d'Ivoire: A Strategic Hub for West Africa
Côte d'Ivoire has positioned itself as one of the most dynamic healthcare and research ecosystems in the region. By establishing Gaya Pharma CI, we are strengthening our footprint in West Africa to better serve patients, institutions, and pharmaceutical partners in Côte d'Ivoire, Senegal, Mali, Ghana, and beyond.
Our subsidiary is designed to become a regional center of excellence for clinical trials, observational studies, and health innovation programs. This expansion enables us to:
- Strengthen clinical research capacity in West Africa
- Implement digital e-registries to collect robust, high-quality patient data
- Conduct real-world evidence (RWE) studies tailored to local health systems and populations
- Improve access to innovative therapies through Patient Support Programs (PSPs) and Patient Access Programs (PAPs)
- Support ministries of health and local institutions in developing evidence-based healthcare policies
Advanced Digital Tools: e-Registries and Beyond
At Gaya Pharma, we believe that technology is the backbone of reliable healthcare research. With Gaya Pharma CI, we are deploying advanced e-registries and electronic case report forms (e-CRF) that allow:
- Accurate, real-time data collection and monitoring
- Integration with hospital systems for seamless patient follow-up
- Transparency and compliance with international standards
- Reliable insights for public health decision-making
These digital solutions, adapted to African infrastructures, will accelerate evidence generation and empower local healthcare professionals with actionable data.
Driving Real-World Evidence (RWE) Studies in Africa
One of the key missions of Gaya Pharma CI is to lead the development of RWE studies in West Africa. By capturing data from routine clinical practice and patient registries, we aim to:
- Evaluate treatment outcomes in real-world African settings
- Measure the effectiveness and safety of innovative therapies
- Support payers and regulators in health technology assessments
- Provide pharmaceutical partners with evidence to guide market access strategies
RWE studies will not only advance science but also bridge the gap between innovation and accessibility, ensuring that therapies are adapted to the realities of African healthcare systems.
By Africans, For Africa
Our identity as an African CRO is central to our vision. With our headquarters in Morocco and now Gaya Pharma CI in Abidjan, we remain committed to solutions that reflect local contexts, cultural diversity, and regulatory environments.
This expansion embodies our commitment to:
- Building sustainable local expertise in clinical research
- Training healthcare professionals across West Africa
- Supporting governments and institutions with data-driven healthcare strategies
- Positioning Africa as a global leader in research and innovation
Looking Ahead
The launch of Gaya Pharma CI is more than an expansion—it is a long-term investment in Africa's health future. By combining clinical research excellence, advanced digital solutions, and patient-focused programs, we are paving the way for:
- Stronger research ecosystems
- Greater patient access to innovative therapies
- Data-driven healthcare policies that improve lives
With Gaya Pharma CI, we reaffirm our mission: to serve Africa with science, innovation, and compassion.